BACE1 inhibitors: A head group scan on a series of amides
Graphical abstract
Section snippets
Acknowledgments
We cordially thank R. Wermuth, Ch. Schnider, R. Humm, H.-P. Marty, R. Halm, D. Rombach, F. Ricklin, D. Krummenacher and B. Wagner for their skillful technical assistance.
References and notes (22)
- Masui, M.; Hori, A. World Patent WO2011071135, 2011; Chem. Abstr. 2011, 155,...
- Suzuki, S.; Kooriyama, Y. World Patent WO2011077726, 2011; Chem. Abstr. 2011, 155,...
- et al.
J. Med. Chem.
(2013) - et al.
Expert Opin. Ther. Pat.
(2012) - et al.
G
- et al.
J. Neurochem.
(2012) - et al.
J. Heterocycl. Chem.
(1977) - (a)Kobayashi, N.; Kato, A.; Hori, A.; Kanda, Y.; Yasui, K.; Haraguchi, H.; Koriyama, Y.; Yukimasa, A.; Sakaguchi, G.;...(b)Suzuki, Y.; Motoki, T.; Kaneko, T.; Takaishi, M.; Ishida, T.; Takeda, K.; Kita, Y.; Yamamoto, N.; Khan, A.;...(c)Audia, J. E.; Mergott, D. J.; Sheehan, S. M.; Watson, B. M. World Patent WO2009134617, 2009; Chem. Abstr. 2009, 151,...(d)Chen, J. J.; Zhong, W.; Yang, B.; Qian, W.; Lopez, P.; White, R.; Weiss, M.; Judd, T.; Powers, T.; Cheng, Y.;...(e)Clark, C. T.; Cook, A.; Gunawardana, I. W.; Hunt, K. W.; Kallan, N. C.; Siu, M.; Thomas, A. A.; Volgraf, M. World...(f)Dimopoulos, P.; Hall, A.; Kita, Y.; Madin, A.; Shuker, N. L. World Patent WO2012093148, 2012; Chem. Abstr. 2012,...(g)Hall, A.; Farthing, C. N.; Castro Pineiro, J. L. World Patent WO 2012098213, 2012; Chem. Abstr. 2012, 157,...(h)Takaihsi, M.; Ishida, T. World Patent WO2012098461, 2012; Chem. Abstr. 2012, 157,...
- et al.
J. Neurosci.
(2011) - et al.
J. Comput. Aided Mol. Des.
(1995)
Expert Opin. Drug Metabol. Toxicol.
Cited by (50)
The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment
2022, BiochimieCitation Excerpt :Roche's study on fluorinated 1,3-oxazines has shown that the inclusion of CF3 enhances the enzymatic activity in both in vitro and in vivo models and as well as proven to be an effective BBB penetrant in rat models for both Aβ40 and Aβ42 [104]. Fluorine, fluoromethyl, difluoromethyl, or trifluoromethyl substituted in oxazine-based BACE1 inhibitors are well studied by Shionogi [105], Amgen [106], and many more [36,107]. The onset of prion disease begins with the prion protein (PrP), and its structural transition of PrP from PrPc (helix rich) to PrPSc (β-sheet rich), though PrPSc have the same amino acidic sequence as PrPC.
Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: A systematic study
2022, European Journal of Medicinal ChemistryCitation Excerpt :In tautomer 1 the endocyclic nitrogen is the basic center that gets protonated under acidic conditions, while in tautomer 2 the exocyclic nitrogen is the most basic center. In Table 1 the values of the best pKa predicting software for both tautomer 1 (Jaguar) [53] and tautomer 2 (Percepta Galas) [51] are given, as well as the best correlating predictions for CHI LogP (BioByte cLogP) [60] and EPSA (Stardrop NOSP TPSA) [54]. A detailed discussion of the pKa, LogP and TPSA prediction software evaluation is provided further.
Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors
2022, Bioorganic and Medicinal Chemistry LettersFacile Construction of an Amino-1,3-Oxazine Scaffold using Burgess Reagent Under Mild Conditions
2021, Tetrahedron Letters
- †
Current address: Autifony S.r.l., Via Fleming 4, 37135 Verona, Italy.
- ‡
Current address: Warner Chilcott, Xerox Technology Park, Dundalk, Co. Louth, Ireland.